Arthropathy in acromegaly: a questionnaire-based estimation of motor disability and its relation with quality of life and work productivity.
Acromegaly
Articular impairment
Complication
Gender
Osteoarthritis
Rehabilitation
Journal
Pituitary
ISSN: 1573-7403
Titre abrégé: Pituitary
Pays: United States
ID NLM: 9814578
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
pubmed:
30
4
2019
medline:
24
3
2020
entrez:
30
4
2019
Statut:
ppublish
Résumé
Arthropathy is a common and disabling complication of acromegaly. Since in this condition radiological findings rarely correspond to functional impairment, we elected to quantify in a large cohort of acromegalic patients: the degree of motor disability compared with data from general population, the impact of joint involvement on quality of life and work productivity, and to look for associated factors. In 211 acromegalic patients, 131 with controlled disease and 80 with active disease, eight validated scales were used to evaluate the (i) prevalence and distribution of arthropathy, (ii) degree of motor disability and joint symptoms (VAS, AIMS symptoms and WOMAC), (iii) quality of life (AcroQoL and PASQ) and work capability (WPAI:GH) as consequences of joint complications. Using the WOMAC questionnaire, for which population based normative values are available, a significantly higher prevalence and severity of motor disability was detected in acromegalics compared to the general population from literature. The results provided by the different questionnaires turned out to be highly concordant. All measures of motor disability correlated both with impaired quality of life and motor disability and were worse in females and in patients with higher BMI. The questionnaires VAS, AIMS symptoms, and WOMAC (this latter both as a whole and with its functionality subscale), with their scores, proved to be the most adequate tools to evaluate motor disability and its consequences on both quality of life and work productivity in acromegaly. Female gender and higher BMI are associated with worse articular symptoms.
Identifiants
pubmed: 31032537
doi: 10.1007/s11102-019-00966-8
pii: 10.1007/s11102-019-00966-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
552-560Références
Pharmacoeconomics. 1993 Nov;4(5):353-65
pubmed: 10146874
N Engl J Med. 2000 Apr 20;342(16):1171-7
pubmed: 10770982
Osteoarthritis Cartilage. 2003 Aug;11(8):551-60
pubmed: 12880577
JAMA. 1963 Sep 21;185:914-9
pubmed: 14044222
J Clin Endocrinol Metab. 2004 Feb;89(2):598-603
pubmed: 14764768
Health Qual Life Outcomes. 2004 Feb 27;2:13
pubmed: 14987332
Endocrinol Metab Clin North Am. 1992 Sep;21(3):615-31
pubmed: 1521515
J Clin Endocrinol Metab. 2005 May;90(5):2731-9
pubmed: 15741257
J Endocrinol Invest. 2005;28(8 Suppl):24-31
pubmed: 16323826
Eur J Endocrinol. 2006 Aug;155(2):269-77
pubmed: 16868140
J Clin Endocrinol Metab. 2008 Oct;93(10):3853-9
pubmed: 18647806
Growth Horm IGF Res. 2010 Jun;20(3):226-33
pubmed: 20194043
Clin Exp Rheumatol. 1991 Jan-Feb;9(1):47-50
pubmed: 2054967
Ann Rheum Dis. 2011 Feb;70(2):320-5
pubmed: 21131647
Semin Arthritis Rheum. 2011 Oct;41(2):139-48
pubmed: 21546065
Eur J Endocrinol. 2012 Mar;166(3):407-13
pubmed: 22170798
Eur J Endocrinol. 2012 Aug;167(2):235-44
pubmed: 22645199
Pituitary. 2014 Feb;17(1):44-52
pubmed: 23344976
Clin Rheumatol. 2013 Jul;32(7):991-8
pubmed: 23512376
Growth Horm IGF Res. 2013 Oct;23(5):159-64
pubmed: 23810124
Best Pract Res Clin Rheumatol. 2014 Feb;28(1):5-15
pubmed: 24792942
Neuroendocrinology. 2016;103(1):86-95
pubmed: 25633971
J Rheumatol. 2016 Feb;43(2):433-9
pubmed: 26628608
Eur J Endocrinol. 2017 Jun;176(6):779-790
pubmed: 28348071
Arthritis Rheum. 1988 Aug;31(8):1022-7
pubmed: 2900639
J Rheumatol. 1988 Dec;15(12):1833-40
pubmed: 3068365
Ann Rheum Dis. 1971 May;30(3):243-58
pubmed: 4253632
Gerontologist. 1969 Autumn;9(3):179-86
pubmed: 5349366
Clin Pharmacol Ther. 1983 Aug;34(2):234-9
pubmed: 6872418
Arthritis Rheum. 1982 Sep;25(9):1048-53
pubmed: 7126289
Pain. 1975 Dec;1(4):379-84
pubmed: 800639